Q-omics provides the consensus-scored MYG1P1 profile across patient tissues and cancer cell-line models. MYG1P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, MYG1P1 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, MYG1P1 RNA expression shows 6,744 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight TGCT, KICH, and LSCC as cancer lineages where MYG1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYG1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYG1P1 survival associations across molecular data types. MYG1P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYG1P1 RNA expression–survival associations across cancer types. High MYG1P1 expression shows unfavorable associations in TGCT, THYM, MESO, UVM, KIRC and LUAD. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify TGCT as the clearest survival context for MYG1P1 RNA expression.
This table summarizes MYG1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MYG1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYG1P1 shows lower tumor expression in KICH and PAAD and higher tumor expression in COAD and KIRP. The KICH box plot shows higher MYG1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.077, t-test p < 0.001).
This table shows molecular features associated with MYG1P1 in patient tissues and cancer cell lines. In patient samples, MYG1P1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
